Abstract
We have developed a series of 6, 7-disubstituted-4-(arylamino) quinazoline derivatives that functioned as irreversible EGFR inhibitors, and these compounds exhibited excellent enzyme inhibition potency. As compared with afatinib, some of them showed significantly enhanced activities towards H1975 cells (EGFR-T790M). Furthermore, the optimized compounds 7q and 8f also demonstrated good pharmacokinetic profiles, oral bioavailability as well as excellent in vivo efficacy in H1975 and HCC827 xenografts at a non-toxic dose. Based on the improved safety and efficacy against EGFR-T790M resistance, 7q and 8f are promising candidates for further studies.
Keywords:
A-431; EGFR-T790M; H1975; HCC827; Quinazoline derivatives.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Afatinib
-
Animals
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / pharmacology
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Dose-Response Relationship, Drug
-
Drug Discovery*
-
ErbB Receptors / antagonists & inhibitors*
-
ErbB Receptors / metabolism
-
Female
-
Humans
-
Mice
-
Mice, Inbred BALB C
-
Mice, Nude
-
Molecular Structure
-
Neoplasms, Experimental / drug therapy
-
Neoplasms, Experimental / pathology
-
Protein Kinase Inhibitors / chemical synthesis
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacokinetics
-
Protein Kinase Inhibitors / pharmacology*
-
Quinazolines / chemical synthesis
-
Quinazolines / chemistry
-
Quinazolines / pharmacokinetics
-
Quinazolines / pharmacology*
-
Structure-Activity Relationship
-
Xenograft Model Antitumor Assays
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Quinazolines
-
Afatinib
-
ErbB Receptors